MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings
Authors:
Open Access
Abstract
No abstract availableKeywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Breakthrough cases of mpox: One-dose vaccination is associated with milder clinical manifestationsJournal of Infection and Public Health, 2024
- JYNNEOS™ effectiveness as post-exposure prophylaxis against mpox: Challenges using real-world outbreak dataVaccine, 2024
- Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort studyeClinicalMedicine, 2024
- Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational studyThe Lancet Infectious Diseases, 2023
- Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individualsCell Host & Microbe, 2023
- Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategiesVaccine, 2023
- Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational studyThe Lancet Infectious Diseases, 2023
- MonkeypoxThe Lancet, 2022
- The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platformVaccine, 2021
- Vaccinating against monkeypox in the Democratic Republic of the CongoAntiviral Research, 2019